Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Chupp

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology|September 12, 2018
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparisonWilliam Busse, Geoffrey Chupp, Hiroyuki Nagase, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 26, 2019
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthmaGeoffrey Chupp, Njira L Lugogo, Joel N Kline, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 8, 2025
Impact of demographics on mepolizumab effectiveness in severe asthma: One-year REALITI-A subanalysis (12/12 words)Geoffrey Chupp, Liam G Heaney, Girolamo Pelaia, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2021
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension StudyGerald J Gleich, Florence Roufosse, Geoffrey Chupp, et al.
The Journal of Experimental Medicine|October 27, 2010
Epithelial reticulon 4B (Nogo-B) is an endogenous regulator of Th2-driven lung inflammationPaulette L Wright, Jun Yu, Y P Peter Di, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 14, 2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthmaJonathan Corren, Michael E Wechsler, Geoffrey Chupp, et al.
ERJ Open Research|November 12, 2025
Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two yearsGiorgio W Canonica, Diego Bagnasco, Jason K Lee, et al.
The Journal of Allergy and Clinical Immunology|February 22, 2020
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapyPeter Howarth, Geoffrey Chupp, Linda M Nelsen, et al.
The European Respiratory Journal|September 2, 2017
Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studiesGeoffrey Chupp, Michel Laviolette, Lauren Cohn, et al.
American Journal of Respiratory and Critical Care Medicine|June 24, 2026
Reply to Siddiqui et al., Godbout et al., and to Chang and MaoGeoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology|September 12, 2018
Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparisonWilliam Busse, Geoffrey Chupp, Hiroyuki Nagase, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|February 26, 2019
Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthmaGeoffrey Chupp, Njira L Lugogo, Joel N Kline, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 8, 2025
Impact of demographics on mepolizumab effectiveness in severe asthma: One-year REALITI-A subanalysis (12/12 words)Geoffrey Chupp, Liam G Heaney, Girolamo Pelaia, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2021
Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension StudyGerald J Gleich, Florence Roufosse, Geoffrey Chupp, et al.
The Journal of Experimental Medicine|October 27, 2010
Epithelial reticulon 4B (Nogo-B) is an endogenous regulator of Th2-driven lung inflammationPaulette L Wright, Jun Yu, Y P Peter Di, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 14, 2022
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthmaJonathan Corren, Michael E Wechsler, Geoffrey Chupp, et al.
ERJ Open Research|November 12, 2025
Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two yearsGiorgio W Canonica, Diego Bagnasco, Jason K Lee, et al.
The Journal of Allergy and Clinical Immunology|February 22, 2020
Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapyPeter Howarth, Geoffrey Chupp, Linda M Nelsen, et al.
The European Respiratory Journal|September 2, 2017
Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studiesGeoffrey Chupp, Michel Laviolette, Lauren Cohn, et al.
American Journal of Respiratory and Critical Care Medicine|June 24, 2026
Reply to Siddiqui et al., Godbout et al., and to Chang and MaoGeoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
Pageof 6